United Kingdom
The Netherlands, Switzerland, Austria, Italy, Sweden, Denmark, France, Poland
Israel, Greece

General project infromation

In an era of increasing emergence of drug resistance and lack of new antibiotics, old off-patent antibiotics are increasingly being prescribed to patients. However, many of these were developed in an age before the advent of a structured process for drug assessment and approval, and the establishment of clinical efficacy and effectiveness in randomized controlled trials in particular. The AIDA project aims to answer the question of clinical effectiveness and optimal dosing of five off-patent-antibiotics: colistin, fosfomycin, nitrofurantoin, minocyclin and rifampicin.  The aim of the studies is to integrate all aspects that play a role in defining the optimal antibiotic choices and dosing regimens of the off-patent antibiotics in the treatment of infections caused by multi-resistant bacteria. Three randomized controlled trials as well as microbiological and PK/PD studies will assess clinically-relevant outcomes for the individual patient, PK/PD assessment and correlation between PK/PD indices and clinical outcomes, including efficacy, toxicity and emergence of drug resistance.

To help reduce the burden of antibiotic resistant infections in and outside Europe, AIDA comprises three clinical trials, each comparing two antibiotic regimens in infections caused by MDR bacteria (WP1,2,3). Each of the three clinical studies is linked to a complementary work package (WP4) that will perform additional PK/PD investigations relevant to the purpose of this call. The four main objectives in each of the three trials are to assess clinical effectiveness using optimal methodology, to perform microbiological sampling with bacteriological outcome and emergence of drug resistance, and determine exposures by performing PK studies.

Under FP7, AIDA presents a clear example of extended European cooperation with 14 partners from 11 different countries.

EU map partners